BiomX

PHGE

Market cap $15.4M

Overview Fund Trends Analyst Outlook Journalist POV

0.5800 USD

+0.0053

0.92%

At close Updated Oct 24, 4:00 PM EDT

Pre-market

After hours

0.5896

+0.0096

1.66%

1 day

0.92%

5 days

3.41%

1 month

9.43%

3 months

32.42%

6 months

-5.01%

Year to date

-26.11%

1 year

-34.87%

5 years

-99.03%

10 years

-99.4%

About: BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Employees: 57

Healthcare Drug Manufacturers - General